Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Acute Myeloid Leukemia Pipeline Insight' report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Acute Myeloid Leukemia Treatment Landscape. Click here to read more @ Acute Myeloid Leukemia Pipeline Outlook
Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
In March 2025, Janssen Research & Development, LLC conducted a study to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in Phase 1 (Part 1 - Dose Escalation) and assess its safety and tolerability at RP2D in Phase 1 (Part 2 - Dose Expansion). The Phase 2 part of the study aims to evaluate the efficacy of bleximenib at the RP2D.
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. The study's objective is to evaluate the safety and efficacy of AK117 + azacitidine in AML patients.
DelveInsight's Acute Myeloid Leukemia Pipeline analysis depicts a robust space with 110+ active players working to develop 120+ pipeline treatment therapies.
The leading Acute Myeloid Leukemia Companies such as GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others.
Promising Acute Myeloid Leukemia Therapies such as OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
Discover groundbreaking developments in Acute Myeloid Leukemia therapies! Gain in-depth knowledge of key Acute Myeloid Leukemia clinical trials, emerging drugs, and market opportunities @ Acute Myeloid Leukemia Clinical Trials Assessment
Acute Myeloid Leukaemia Emerging Drugs Profile
Uproleselan: GlycoMimetics
GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. Uproleselan is designed to bind to E-selectin and block the normal processes controlled by E-selectin. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect via NF-kB signaling. Uproleselan is designed to provide a novel approach to disrupting established mechanisms of leukemic cell resistance. It is believed that by binding to E-selectin, uproleselan pushes AML cells out of their protective niche, blocks cellular communication signals that promote survival, and sensitizes cancer cells to the toxic effects of chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of Acute Myeloid Leukemia (AML).
BST-236: BioSight
Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. Currently, the drug is in Phase II stage of its development for the treatment of Acute Myeloid Leukemia (AML).
MK-0482: Merck Sharp & Dohme LLC
MK-0482, a novel humanized IgG4 mAb targeting ILT3, is undergoing phase I evaluation ±pembrolizumab (pembro) in advanced solid tumors. MK-0482 ± pembro was generally well tolerated, and combination therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts. Currently, the drug is in Phase I stage of its development for the treatment of AML.
Ziftomenib - Kura Oncology
Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLL protein complex and exhibits downstream effects on HOXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML. Ziftomenib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML. Currently, the drug is in Phase I/II stage of its development for the treatment of AML.
SENTI 202: Senti Biosciences
SENTI-202 is a first in class Logic-gated CAR-NK product engineered with an OR and a NOT Logic Gate gene circuit approach to enhance therapeutic efficacy and safety, with additional arming via expression of calibrated release IL-15 (crIL-15). A dual targeting activating CAR (aCAR) that recognizes both CD33 and FLT3 tumor antigens improves the anti-tumor activity, ensuring the targeting of AML blasts and LSCs. Currently, the drug is in Preclinical stage of its development for the treatment of AML.
The Acute Myeloid Leukemia pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment.
Acute Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market
Stay informed about the Acute Myeloid Leukemia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acute Myeloid Leukemia Unmet Needs
Acute Myeloid Leukemia Companies
GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others.
The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the Acute Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives
Scope of the Acute Myeloid Leukemia Pipeline Report
Coverage- Global
Acute Myeloid Leukemia Companies- GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others.
Acute Myeloid Leukemia Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research–Access the Full Acute Myeloid Leukemia Pipeline Analysis Today! @ Acute Myeloid Leukemia Drugs and Companies
Table of Content
Introduction
Executive Summary
Acute myeloid leukaemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Acute myeloid leukaemia – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Uproleselan: GlycoMimetics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BST-236: BioSight
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MK-0482: Merck Sharp & Dohme LLC
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
SENTI 202: Senti Biosciences
Drug profiles in the detailed report…..
Inactive Products
Acute myeloid leukaemia Key Companies
Acute myeloid leukaemia Key Products
Acute myeloid leukaemia- Unmet Needs
Acute myeloid leukaemia- Market Drivers and Barriers
Acute myeloid leukaemia- Future Perspectives and Conclusion
Acute myeloid leukaemia Analyst Views
Acute myeloid leukaemia Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 days ago
- CTV News
Appeal filed against proposed Exchange District development
The Sanford Building and Maw's Garage in Winnipeg's Exchange District are both pictured in April 2025. (Michelle Gerwing/CTV News Winnipeg) A city committee will hear an appeal to a proposed addition to two Exchange District heritage buildings next week. According to the property and development committee's agenda, the president of a nearby condo complex has appealed the decision to create a nine-storey rooftop addition above the Sanford Building and Maw's Garage near Bannatyne Avenue and King Street. In a letter, Alan Tate said the proposed development is out of scale and out of character for the area, and would impact the proposed development of the Exchange District as a National Historic Site. The letter also claims the development could physically impact neighbouring structures, particularly his own building on Princess Street. A permit was granted for the project in April by the same committee. The matter will be heard when the committee meets June 11.
Toronto Sun
3 days ago
- Toronto Sun
GUNTER: Taxpayers foot the bill for politicians' EV delusions
A Ford Mustang Mach-E electric vehicle (EV) charges via a CCS DC fast charger from Electrify America at a shopping mall parking lot in Torrance, California, on February 23, 2024. Photo by PATRICK T. FALLON / AFP via Getty Images Among gambling addicts, it's called 'chasing your losses,' making ever larger and riskier bets to try to win back the money lost for initial bets. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Canadian politicians are now chasing their losses on electric vehicles (EVs). In the last five years, the federal, Ontario and Quebec governments have made enormous gambles on the future of the EV industry. According to the Parliamentary Budget Office, the total these three governments have bet on EVs replacing internal combustions engines is in excess of $52 billion. That's just the tax money pledged to EV makers. It doesn't include billions more for subsidies to consumers to encourage them to buy EVs or to develop a network of charging stations across this vast land mass. If Canada were to achieve the federal mandate that all new cars and light-duty trucks sold in the country be EVs by 2035, the cost of manufacturing plants, battery plants, subsidies to buyers and charging infrastructure could easier soar to $200 billion, about 75 per cent of which would come from taxpayers. Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. The whole scheme is a fake market with phoney stimulus largely created by government command, not consumer demand. That's also just the price of this one slice of the politicians' 'green' transition. Let's not even bring up the cost of making Canada's entire power grid net zero at a time when government actions will be doubling the demand for electricity to charge EVs, heat homes without using natural gas, oil or coal, and build giant computing centres for the coming AI revolution. Given all those potential gigantic problems from the political rush to save the planet with net-zero cars and power generation, maybe I shouldn't focus on the federal Liberals' announcement over the weekend that they will be bringing back Ottawa's $5,000 per vehicle 'incentive' to buyers of EVs. This advertisement has not loaded yet, but your article continues below. Make no mistake, this is largely a government goodie for the upper-middle class. The typical EV buyer makes in excess of $90,000 a year and is buying the EV as a second or even third car. However, if Ottawa, Ontario and Quebec are going to maintain the fantasy that Canadian drivers can all be switched over to the electric vehicles that will be built in the mega-factories those governments have committed taxpayer billions to, then these subsidies have to be reinstated so that sales of EVs can be made to look, artificially, as though they are strong, when in fact they are not. After the federal incentive program ran out of cash in January, EVs sales across Canada fell 41 per cent in February and 45 per cent in March, versus those same months a year earlier. This advertisement has not loaded yet, but your article continues below. You will often hear 'green' politicians, bureaucrats and environmentalists claim the market for EVs is growing rapidly. They're not. The second governments stopped fanning the fire with generous subsidies, the flames burned down. Also, despite the tens of billions given by governments to auto manufacturers, in the last six months Honda, Ford, General Motors, Stellantis (Chrysler) and Toyota have all suspended plans to construct EV plants. My favourite was Ford's decision to switch a planned EV plant to production of its F-250 Super Duty pickup. Take that, EV promoters. On top of the big names, Lion Electric, a Quebec-based maker of electric transport trucks, tried to switch from trucks to buses last year to find investors. It is now in creditor protection. This advertisement has not loaded yet, but your article continues below. The future in Canada of Swedish battery maker Northvolt — and the $7 billion given to it by the feds and the Quebec government — remains unclear, too. At present, of the over $50 billion committed to EV manufacturing by the federal government, Ontario and Quebec, about 70 per cent is delayed, in trouble or in default. Politicians allowed themselves to get swept up in the EV euphoria. Unfortunately, they dragged Canadians and their tax money along for the ride. Read More Celebrity Columnists Canada Canada Toronto & GTA
Cision Canada
3 days ago
- Cision Canada
Royal Bank of Canada announces NVCC AT1 Limited Recourse Capital Notes issue Français
TORONTO, June 4, 2025 /CNW/ - Royal Bank of Canada (TSX: RY) and (NYSE RY) today announced the offering of US$1.25 billion of non-viability contingent capital (NVCC) Additional Tier 1 (AT1) Limited Recourse Capital Notes, Series 6 (the "LRCNs"). The securities offered are registered with the U.S. Securities and Exchange Commission (the "SEC"). The LRCNs will bear interest at a rate of 6.750 per cent annually, payable quarterly, for the initial period ending August 24, 2030. Thereafter, the interest rate on the LRCNs will reset every five years at a rate equal to the prevailing 5-year U.S. Treasury Rate plus 2.815 per cent. The LRCNs will mature on August 24, 2085. The expected closing date of the offering is June 11, 2025, subject to customary closing conditions. RBC Capital Markets, Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and UBS Securities LLC are the joint book-running managers for the offering. Concurrently with the issuance of the LRCNs, the bank will issue NVCC Non-Cumulative 5-Year Fixed Rate Reset First Preferred Shares, Series BY ("Preferred Shares Series BY") to be held by Computershare Trust Company of Canada as trustee for Leo LRCN Limited Recourse Trust TM (the "Limited Recourse Trust"). In case of non-payment of interest on or principal of the LRCNs when due, the recourse of each LRCN holder will be limited to that holder's proportionate share of the Limited Recourse Trust's assets, which will consist of Preferred Shares Series BY except in limited circumstances. The bank may redeem the LRCNs on August 24, 2030 and on each February 24, May 24, August 24, and November 24 thereafter, only upon the redemption by the bank of the Preferred Shares Series BY held in the Limited Recourse Trust, in accordance with the terms of such shares and with the prior written approval of the Superintendent of Financial Institutions (Canada), in whole on not less than 10 nor more than 60 days' prior notice. Net proceeds from this transaction will be used for general business purposes. A registration statement relating to the offering has been filed with the SEC and is effective. The offering is being made only by means of a prospectus supplement and a base prospectus. Copies of the preliminary prospectus supplement and the base prospectus for the offering may be obtained free of charge by visiting EDGAR on the SEC's website at Alternatively, you may obtain copies of the final prospectus supplement, when available, and the base prospectus for this offering by contacting RBC Capital Markets, LLC, by calling (866)-375-6829, or by e-mailing [email protected]. This press release is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. For further information, please contact: Investor Contact: Asim Imran, Investor Relations, [email protected], 416-955-7804 Media contact: Gillian McArdle, Financial Communications, [email protected], 416-842-4231 SOURCE Royal Bank of Canada
